当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Pertussis after end of a mass vaccination project--end of the "vaccination honey-moon".

Pertussis after end of a mass vaccination project--end of the "vaccination honey-moon".

Abstract：

:After 16 years of no vaccination against pertussis in Sweden, mass vaccination of infants and catch-up vaccination of children up to 10 years with a monocomponent pertussis toxoid vaccine was performed in the Greater Gothenburg area of Sweden between 1995 and 1999. At the end of the project in February 1999, 56% of all 10 year old children born in the Greater Gothenburg area had received 3 doses of the pertussis toxoid. No booster doses were given. This led to a temporary almost complete elimination of the disease. The aim of the present study was to follow the incidence of pertussis after end of the mass vaccination project (1999-2009) as it is reflected by laboratory verified cases (cultures and/or PCR) and pertussis hospitalizations. A reemergence of pertussis was seen from the end of 1999 with a peak in 2004 followed by a decrease when booster doses to both 6 and 10 year old children were introduced in 2005-2006. From July 1, 1999 through December 31, 2009 a total of 1973 cases were diagnosed with culture or PCR. The disease was prevalent in all age groups. The highest documented incidence was seen in infants younger than 12 months. 450 patients with verified pertussis had received 3 doses of the pertussis toxoid vaccine in the mass vaccination project and some other trials (comprising a total of 69,423 children). The mean time from the last dose to the laboratory verification of pertussis was 5 years in these 450 cases. There were 128 hospitalizations, 106 of which were in infants. In conclusion, pertussis is still not eliminated from the area. Booster doses are needed but the numbers and optimal timing are not known.

journal_name

Vaccine

journal_title

Vaccine

authors

Trollfors B,Dotevall L,Sundh V,Welinder-Olsson C

doi

10.1016/j.vaccine.2011.01.021

subject

Has Abstract

pub_date

2011-03-16 00:00:00

pages

2444-50

issue

13

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(11)00049-1

journal_volume

29

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.

    abstract：BACKGROUND:Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) has recently been implemented to prevent infant pertussis. Tdap is still not routinely recommended in Thailand, and there are limited data to support or challenge this strategy. OBJECTIVES:The primar...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.01.074

    authors： Sompagdee N,Anuwutnavin S,Phongsamart W,Senawong S,Umrod P,Robkhonburi A

    更新日期：2020-03-10 00:00:00

  • Leprosy vaccine: influence of dissolved oxygen levels on growth of a candidate strain (Mycobacterium w), and storage stability of the vaccine.

    abstract：:The growth of Mycobacterium w, a candidate strain for leprosy vaccine in submerged culture, was inhibited by the presence of over 40% oxygen saturation in the medium. Intracellular levels of superoxide dismutase and catalase were very low in the beginning. However, under controlled oxygenation, these levels increased ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00022-x

    authors： Mukhopadhyay A,Panda AK,Pandey AK

    更新日期：1998-08-01 00:00:00

  • Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials.

    abstract：BACKGROUND:Efforts to develop a Clostridium difficile vaccine are underway; identification of patients at risk for C. difficile infection (CDI) is critical to inform vaccine trials. We identified groups at high risk of CDI ≥ 2 8 days after hospital discharge. METHODS:Hospital discharge data and pharmacy data from two ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.09.078

    authors： Baggs J,Yousey-Hindes K,Ashley ED,Meek J,Dumyati G,Cohen J,Wise ME,McDonald LC,Lessa FC

    更新日期：2015-11-17 00:00:00

  • Antigen dependent and independent mechanisms that sustain serum antibody levels.

    abstract：:In this article, we review three mechanisms that contribute to sustaining serum antibody levels: (i) long-lived plasma cells; (ii) persisting or cross-reactive antigen, and (iii) polyclonal activation of all memory B cells. We also present a quantitative analysis of the secondary immune response that reveals the relat...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/s0264-410x(03)00198-1

    authors： Traggiai E,Puzone R,Lanzavecchia A

    更新日期：2003-06-01 00:00:00

  • Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

    abstract：:Genetically modified bacterial flagellin (Fla), a Toll-like receptor-5 (TLR5) ligand, was evaluated as a fusion partner for human papillomavirus (HPV) L2-based immunogens in two animal challenge models; either cutaneous inoculation of rabbits with HPV 'quasivirions' containing cottontail rabbit papillomavirus (CRPV) g...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.04.032

    authors： Kalnin K,Tibbitts T,Yan Y,Stegalkina S,Shen L,Costa V,Sabharwal R,Anderson SF,Day PM,Christensen N,Schiller JT,Jagu S,Roden RB,Almond J,Kleanthous H

    更新日期：2014-06-12 00:00:00

  • Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine.

    abstract：:TA-CIN is a vaccine that comprises the human papillomavirus (HPV) type 16 L2, E6 and E7 as a single fusion protein. In a mouse model, TA-CIN effectively prevented outgrowth of HPV16-positive tumour cells. To assess the safety and immunogenicity of TA-CIN, a dose escalating (26, 128, 533 micro g), double blind and plac...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0264-410x(02)00350-x

    authors： de Jong A,O'Neill T,Khan AY,Kwappenberg KM,Chisholm SE,Whittle NR,Dobson JA,Jack LC,St Clair Roberts JA,Offringa R,van der Burg SH,Hickling JK

    更新日期：2002-10-04 00:00:00

  • Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up.

    abstract：:In order to evaluate the long-term immunity 2 and 3 years after booster vaccination against tick-borne encephalitis (TBE) following time intervals 3 years and longer since last TBE immunization, 195 (mean age 50.5+/-15.1 years) and 240 subjects (mean age 47.0+/-15.4 years), respectively, who had received a single boos...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.01.116

    authors： Rendi-Wagner P,Paulke-Korinek M,Kundi M,Wiedermann U,Laaber B,Kollaritsch H

    更新日期：2007-06-28 00:00:00

  • Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

    abstract：:A conjugate vaccine against meningococcus A and C was prepared using the non-toxic mutant of diphtheria toxin CRM 197 as a carrier protein. Capsular polysaccharides of Neisseria meningitidis group A and C were hydrolysed and the resulting oligosaccharides were then coupled to CRM 197 in order to obtain conjugates with...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(92)90091-w

    authors： Costantino P,Viti S,Podda A,Velmonte MA,Nencioni L,Rappuoli R

    更新日期：1992-01-01 00:00:00

  • Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.

    abstract：BACKGROUND:Therapeutic vaccination is a novel treatment approach for chronic hepatitis B, but only had limited success so far. We hypothesized that optimized vaccination schemes have increased immunogenicity, and aimed at increasing therapeutic hepatitis B vaccine efficacy. METHODS:Modified Vaccinia virus Ankara (MVA)...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.12.060

    authors： Backes S,Jäger C,Dembek CJ,Kosinska AD,Bauer T,Stephan AS,Dišlers A,Mutwiri G,Busch DH,Babiuk LA,Gasteiger G,Protzer U

    更新日期：2016-02-10 00:00:00

  • Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors.

    abstract：:To evaluate the perceived pain, other adverse events, and immunogenicity of influenza virus vaccine administered by needle-free jet injector (JI) compared with that of vaccine administered by needle and syringe (N&S), we randomly assigned 304 healthy young adults to receive one of three dosages (0.5, 0.3, or 0.2 ml) o...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0264-410x(01)00225-0

    authors： Jackson LA,Austin G,Chen RT,Stout R,DeStefano F,Gorse GJ,Newman FK,Yu O,Weniger BG,Vaccine Safety Datalink Study Group.

    更新日期：2001-09-14 00:00:00

  • Urticaria following varicella vaccine associated with gelatin allergy.

    abstract：:An uncommon reaction to varicella vaccine has been urticaria. Based on two reports of urticaria believed to be due to gelatin in recipients of measles-mumps-rubella vaccine, we suspected gelatin as the cause of generalized urticaria in two children after varicella vaccination. Intradermal testing with gelatin yielded ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00209-6

    authors： Singer S,Johnson CE,Mohr R,Holowecky C

    更新日期：1999-01-28 00:00:00

  • Sampling methods for the study of pneumococcal carriage: a systematic review.

    abstract：:Streptococcus pneumoniae is an important pathogen worldwide. Accurate sampling of S. pneumoniae carriage is central to surveillance studies before and following conjugate vaccination programmes to combat pneumococcal disease. Any bias introduced during sampling will affect downstream recovery and typing. Many variable...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2012.08.080

    authors： Gladstone RA,Jefferies JM,Faust SN,Clarke SC

    更新日期：2012-11-06 00:00:00

  • Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients.

    abstract：:A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating beta-propriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adverse reactions and e...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(94)00049-s

    authors： Wilde H,Glueck R,Khawplod P,Cryz SJ,Tantawichien T,Thipkong P,Chomchey P,Prakongsri S,Benjavongkulchai M,Sumboonanondha A

    更新日期：1995-04-01 00:00:00

  • Parents' preferences for seasonal influenza vaccine for their children in Japan.

    abstract：:In Japan, trivalent inactivated influenza vaccine is the only approved influenza vaccine. It is typically administrated by hypodermic injection, and children under 13 years of age are recommended to be vaccinated two times during each winter season. Live-attenuated influenza vaccine (LAIV) is administered by a thimero...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.07.002

    authors： Shono A,Kondo M

    更新日期：2014-09-03 00:00:00

  • Pertussis immunization in paediatric healthcare workers: knowledge, attitudes, beliefs, and behaviour.

    abstract：:Healthcare workers' (HCWs) knowledge, attitudes, and beliefs regarding pertussis immunization were assessed and compared to the rate of vaccine uptake. A questionnaire was distributed to employees at a paediatric and maternity tertiary care centre. Respondents were then offered a dose of the tetanus, diphtheria, and a...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.12.060

    authors： Top KA,Halperin BA,Baxendale D,MacKinnon-Cameron D,Halperin SA

    更新日期：2010-03-02 00:00:00

  • No evidence for priming response in Galleria mellonella larvae exposed to toxin protein PirA2B2 from Photorhabdus luminescens TT01: An association with the inhibition of the host cellular immunity.

    abstract：:There is accumulating evidence that many invertebrates including insects can acquire enhanced immune protection against subsequently pathogens infection through immune priming. However, whether the toxin protein from pathogenic bacteria can induce such priming response remains unclear. Here we cloned, expressed and pu...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.09.046

    authors： Wu G,Yi Y,Sun J,Li M,Qiu L

    更新日期：2015-11-17 00:00:00

  • Stable expression and secretion of the B-cell epitope of rodent malaria from Mycobacterium bovis BCG and induction of long-lasting humoral response in mouse.

    abstract：:The live bacterial vaccine Mycobacterium bovis BCG (BCG) is a vehicle worth noticing for various protective antigens. The gene encoding the B-cell epitope of the oligopeptide repeating in the circumsporozoite protein (C.S. protein) of the rodent malaria parasite, Plasmodium yoelii, was inserted into the plasmid vector...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(95)00131-j

    authors： Matsumoto S,Yanagi T,Ohara N,Wada N,Kanbara H,Yamada T

    更新日期：1996-01-01 00:00:00

  • Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs.

    abstract：:In this study, the potential of N-Trimethyl chitosan (TMC, degree of quaternization 50%) and dextran microparticles for pulmonary delivery of diphtheria toxoid (DT) was investigated. The antigen-containing microparticles were prepared by drying of an aqueous solution of polymer and DT through a supercritical fluid (SC...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.05.064

    authors： Amidi M,Pellikaan HC,Hirschberg H,de Boer AH,Crommelin DJ,Hennink WE,Kersten G,Jiskoot W

    更新日期：2007-09-17 00:00:00

  • Schistosoma japonicum calcium-binding tegumental protein SjTP22.4 immunization confers praziquantel schistosomulumicide and antifecundity effect in mice.

    abstract：:A family of platyhelminth tegument-specific proteins comprising of one or two calcium ion binding EF-hand and a dynein light chain-like domain, termed tegumental proteins, are considered as candidates of vaccine. In this study, we cloned and characterized SjTP22.4, a novel membrane-anchored tegumental protein in Schis...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.05.056

    authors： Zhang Z,Xu H,Gan W,Zeng S,Hu X

    更新日期：2012-07-20 00:00:00

  • Effectiveness of oral cholera vaccine in preventing cholera among fishermen in Lake Chilwa, Malawi: A case-control study.

    abstract：BACKGROUND:In response to a cholera outbreak among mobile, difficult-to-reach fishermen on Lake Chilwa, Malawi in 2016, a novel vaccine distribution strategy exploited the proven vaccine thermostability. Fishermen, while taking the first vaccine dose under supervision, received the second dose in a sealed bag, and were...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.05.044

    authors： Grandesso F,Kasambara W,Page AL,Debes AK,M'bang'ombe M,Palomares A,Lechevalier P,Pezzoli L,Alley I,Salumu L,Msyamboza K,Sack D,Cohuet S,Luquero FJ

    更新日期：2019-06-19 00:00:00

  • Generation of recombinant pandemic H1N1 influenza virus with the HA cleavable by bromelain and identification of the residues influencing HA bromelain cleavage.

    abstract：:The proteolytic enzyme bromelain has been traditionally used to cleave the hemagglutinin (HA) protein at the C-terminus of the HA2 region to release the HA proteins from influenza virions. The bromelain cleaved HA (BHA) has been routinely used as an antigen to generate antiserum that is essential for influenza vaccine...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.11.101

    authors： Wang W,Suguitan AL Jr,Zengel J,Chen Z,Jin H

    更新日期：2012-01-20 00:00:00

  • Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics.

    abstract：BACKGROUND:Adolescent HPV vaccination in minority and low income populations with high cervical cancer incidence and mortality could reduce disparities. Safety-net primary care clinics are a key delivery site for improving vaccination rates in these populations. PURPOSE:To examine prevalence of HPV initiation (≥ 1 dos...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.11.031

    authors： Tiro JA,Pruitt SL,Bruce CM,Persaud D,Lau M,Vernon SW,Morrow J,Skinner CS

    更新日期：2012-03-16 00:00:00

  • Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.

    abstract：:Human papillomavirus (HPV) infection is highly prevalent and can lead to cancer; the development of safe and efficacious vaccines for HPV is a major public health concern. The two licensed HPV vaccines contain recombinant virus-like particles of HPV 16 and 18; one of such vaccines also protects against HPV types 6 and...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.08.011

    authors： Giacomet V,Penagini F,Trabattoni D,Viganò A,Rainone V,Bernazzani G,Bonardi CM,Clerici M,Bedogni G,Zuccotti GV

    更新日期：2014-09-29 00:00:00

  • Direct immunization of the abomasum or rectum of goats induces local lymph node responses against Haemonchus contortus mucosal antigens.

    abstract：:We investigated several methods to immunize the abomasum (fourth and gastric stomach) of kid goats by direct (abomasal) or distal (rectal or nasal) routes utilizing mucosal antigens isolated from the abomasal parasite, Haemonchus contortus. Direct (ultrasound guided), immunization of the abomasal mucosa together with ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.02.003

    authors： Jasmer DP,Brown WC,Parish S

    更新日期：2011-04-05 00:00:00

  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.

    abstract：:Three separate studies were undertaken in HIV-1 uninfected persons to determine if the adjuvant QS-21 improves the magnitude or kinetics of immune responses induced by recombinant soluble gp120 HIV-1(MN) protein (rsgp120) immunization. The QS-21 was administered at two doses (50 and 100 microg), either alone or in com...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0264-410x(00)00415-1

    authors： Evans TG,McElrath MJ,Matthews T,Montefiori D,Weinhold K,Wolff M,Keefer MC,Kallas EG,Corey L,Gorse GJ,Belshe R,Graham BS,Spearman PW,Schwartz D,Mulligan MJ,Goepfert P,Fast P,Berman P,Powell M,Francis D,NIAID AIDS V

    更新日期：2001-02-28 00:00:00

  • Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.

    abstract：:Pfs25, a Plasmodium falciparum surface protein expressed during zygote and ookinete stages in infected mosquitoes, is a lead transmission-blocking vaccine candidate against falciparum malaria. To enhance immunogenicity, recombinant Pfs25 was chemically conjugated to recombinant nontoxic Pseudomonas aeruginosa ExoProte...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.04.067

    authors： Zhu D,Wu Y,McClellan H,Dai W,Rausch K,Jones D,Aebig J,Barnafo E,Butler B,Lambert L,Narum DL,Duffy PE

    更新日期：2017-05-31 00:00:00

  • Vaccination with a gE-negative bovine herpesvirus type 1 vaccine confers insufficient protection to a bovine herpesvirus type 5 challenge.

    abstract：:In the present study, cross-protection to bovine herpesvirus type 5 (BHV-5) induced by bovine herpesvirus type 1 (BHV-1) vaccination was examined following inoculation of rabbits and calves with a glycoprotein E (gE)-negative BHV-1 vaccine and subsequent challenge with BHV-5. Rabbits (n=5) and calves (n=8) were vaccin...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.01.024

    authors： Silva AD,Spilki FR,Franco AC,Esteves PA,Hübner SO,Driemeier D,Oliveira AP,Rijsewijk F,Roehe PM

    更新日期：2006-04-12 00:00:00

  • Use of rubella seroepidemiological data for assessment of previous vaccination policy and for decision making in response to epidemics in Israel.

    abstract：:We examined the prevalence of rubella antibodies in a representative sample of the Israeli population. Three thousand three hundred and twenty-six sera collected during 1997 and 1998, from an age-stratified general population sample were tested for specific IgG antibodies against rubella. The sero-positivity rates to ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.04.024

    authors： Cohen D,Muhsen Kh,Aboudy Y,Harari H,Mendelson E,Green MS

    更新日期：2006-07-07 00:00:00

  • Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate.

    abstract：:A multi-component vaccine has been defined, which contains six different synthetic 24- to 32-amino acid lipopeptides derived from the sequence of HIV-1 proteins. The physicochemical properties of the lipopeptide components were compatible with multi-dimensional analysis, using RP-HPLC, Edman sequencing, electrospray m...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(99)00196-6

    authors： Klinguer C,David D,Kouach M,Wieruszeski JM,Tartar A,Marzin D,Levy JP,Gras-Masse H

    更新日期：1999-09-01 00:00:00

  • Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines.

    abstract：BACKGROUND:The potential for development of autoimmune diseases after vaccination with new vaccines containing novel adjuvants is a theoretical concern. Randomised, placebo-controlled trials are the best method for assessing a potential causal relationship between an adverse event and vaccination, but usually have a sa...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.01.042

    authors： Tavares Da Silva F,De Keyser F,Lambert PH,Robinson WH,Westhovens R,Sindic C

    更新日期：2013-04-03 00:00:00